Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.

ABSTRACT:

Objectives

Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determine if administration of convalescent plasma to patients with coronavirus disease 2019 increases antibodies to severe acute respiratory syndrome coronavirus 2 and improves outcome.

Design

Double-blind randomized controlled trial.

Setting

Hospital in New York.

Patients

Patients with polymerase chain reaction documented coronavirus disease 2019 infection.

Interventions

Patients were randomized (4:1) to receive 2 U of convalescent plasma versus standard plasma. Antibodies to severe acute respiratory syndrome

SUBMITTER: Bennett-Guerrero E 

PROVIDER: S-EPMC9658886 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature